BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32653455)

  • 21. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
    Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
    Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
    Ou SH; Ziogas A; Zell JA
    J Thorac Oncol; 2009 Jan; 4(1):37-43. PubMed ID: 19096304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
    Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
    Hong S; Rybicki L; Abounader D; Bolwell BJ; Dean R; Gerds AT; Hamilton BK; Hill BT; Jagadeesh D; Kalaycio M; Liu HD; Pohlman B; Sobecks R; Majhail NS
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1141-1144. PubMed ID: 26995694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
    Offidani M; Corvatta L; Polloni C; Centurioni R; Visani G; Brunori M; Gentili S; Catarini M; Samori A; Blasi N; Alesiani F; Caraffa P; Burattini M; Galieni P; Fraticelli P; Ferranti M; Giuliodori L; Leoni P
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):423-32. PubMed ID: 22981966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
    Samaras P; Blickenstorfer M; Haile SR; Siciliano RD; Petrausch U; Mischo A; Zweifel M; Honegger H; Schanz U; Stussi G; Taverna C; Bauer S; Knuth A; Stenner-Liewen F; Renner C
    Swiss Med Wkly; 2011; 141():w13203. PubMed ID: 21630163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer.
    Abdel-Rahman O
    J Comp Eff Res; 2020 Dec; 9(17):1233-1241. PubMed ID: 33275039
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The Prognostic Value of Early Relapse after Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma].
    Tian WW; Ren RR; Zheng FL; Zhu QJ; Gong R; Wang T; Gao ZL; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):535-539. PubMed ID: 33812427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The analysis of prognostic variables in 123 patients with multiple myeloma].
    Xu Y; Deng SH; Mai YJ; Li X; Qi PJ; Zhao YZ; Zou DH; Wang YF; Qian LS; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):330-4. PubMed ID: 17877163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
    Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
    Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of the controlling nutritional status score in patients with multiple myeloma.
    Kamiya T; Ito C; Fujita Y; Ogura S; Mizuno K; Sakurai A; Aisa Y; Nakazato T
    Leuk Lymphoma; 2020 Aug; 61(8):1894-1900. PubMed ID: 32306801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
    Lee H; Duggan P; Chaudhry A; Neri P; Tay J; Rashid-Kolvear F; Bahlis NJ; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e69-e75. PubMed ID: 29158114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma.
    Yang Y; Liu Z; Wang H
    Med Sci Monit; 2020 Jul; 26():e923716. PubMed ID: 32732863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.
    Hungria VTM; Lee JH; Maiolino A; de Queiroz Crusoe E; Martinez G; Bittencourt R; Duarte GO; Fantl DB; Navarro JR; Conte G; Gomez-Almaguer D; Ruiz-Argüelles GJ; Kim K; Shimizu K; Chen W; Huang SY; Chng WJ; Chim CS; Nawarawong W; Durie B
    Ann Hematol; 2019 Apr; 98(4):941-949. PubMed ID: 30729281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.